Hansa Biopharma — Oktober 2025
-
Analyst Consensus på Hansa Biopharma's egen hjemmeside:
Analysts and consensus | Hansa Biopharma
We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.
(www.hansabiopharma.com)
Price target (medianen): SEK 97 og med hele 6 købsanbefalinger (uden Redeye) ..
-
Hansa Biopharma: Jefferies inleder bevakning på Hansa Biopharma med köp och riktkurs 100 kronor.https://www.nordnet.dk/markedet/nyheder/fac00fdf-3379-4320-bb22-17c269e83f93
-
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
• Imlifidase successfully met primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation.
• First clinical data supports imlifidase ability to substantially reduce anti-AAV antibodies to allow administration of gene therapy. -
Hansa Biopharma: ”Pengarna räcker in i 2027”
Hansa Biopharma: ”Pengarna räcker in i 2027”
Hansa Biopharma: ”Pengarna räcker in i 2027”| Håll dig uppdaterad med aktuella ekonominyheter – gratis.
EFN.se (efn.se)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind